Scientific Frontline: Extended "At a Glance" Summary: Personalized DNA Vaccine for Glioblastoma (GNOS-PV01)
The Core Concept: A personalized therapeutic DNA vaccine engineered to target unique neoantigens on a patient's tumor, stimulating the immune system to recognize and eliminate aggressive glioblastoma cells.
Key Distinction/Mechanism: Unlike conventional treatments, this DNA-based platform can target up to 40 unique tumor-specific proteins simultaneously. It successfully transforms immunologically "cold" tumors—which typically evade immune detection—into "hot" tumors vulnerable to targeted immune-mediated eradication.
Major Frameworks/Components:
- Neoantigen Identification: Utilizes computational algorithms to accurately identify and select cancer-specific proteins from various regions of an individual's tumor.
- Synthetic DNA Encoding: Custom-manufactures specialized DNA molecules that encode the unique information for each patient's tumor neoantigens.
- Adjuvant Immunotherapy Intervention: Administered post-operatively during a patient's recovery and radiation treatment to systematically boost immune-cell activity against remaining cancer cells.
.jpg)


.jpg)
.png)






.png)
.png)

